Cited by 700Diabetes Treatment and ManagementHeart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Pantelis A. Sarafidis, Απόστολος Τσάπας·2016·New England Journal of Medicine

DOI 10.1056/nejmc1600827

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1056/nejmc1600827

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion.
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 2

Toto RD, 2013, J Am Soc Nephrol, 24
10.1056/NEJMsr077003 · DOI · Paper page

Sorted by citations

Items 501–600 of 698

Cardioprotective and Renoprotective Effects of the Use of SGLT2 Inhibitors in Diabetes Mellitus Patients
Sukiatno, L., Kusuma, I. Y., & Samodra, G. (2021) · International Conference on Health and Medical Sciences (AHMS) · doi:10.2991/ahsr.k.210127.027 · Cited by 1
Addressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Preoperative ventricular late potentials and the risk of adverse events in patients with obstructive hypertrophic cardiomyopathy undergoing septal myectomy
Zhang, Y., Song, C., Zhu, C., Zhang, J., Zheng, X., Lü, J., Wang, S., & Huang, X. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-367 · Cited by 1
Decision Points in the Management of Patients with Diabetic Kidney Disease
Weir (2021) · The Journal of Family Practice · doi:10.12788/jfp.0217 · Cited by 1
Lo scompenso cardiaco a 360 gradi
Gnerre, G. E. P., & Pasquale, G. D. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.2 · Cited by 1
Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management
Miller (2021) · The Journal of Family Practice · doi:10.12788/jfp.0226 · Cited by 1
Dapagliflozin Add-On Therapy Improves Body Composition and Metabolic Parameters in Overweight Type 2 Diabetic Patients: A Pilot Study
Folco, U. D., Gatti, A., Nardone, M. R., & Tubili, C. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem564 · Cited by 1
Increased Psychological Disorders among Pediatric Population during Covid
AlQaatri, H. A. J. H. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94174 · Cited by 1
Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis
van Husen, G., Virdone, S., Pieper, K. S., Kayani, G., & Fox, K. A. A. (2022) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztac011 · Cited by 1
Evidencia molecular y clínica del beneficio cardiovascular de los inhibidores SGLT2: estado del arte
Gómez, L. S., & Negrete, J. P. G. (2022) · Medicina UPB · doi:10.18566/medupb.v41n2.a07 · Cited by 1
Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
McReelis, K. D., & Lovshin, J. A. (2017) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2017.07.028 · Cited by 2
Faculty Opinions recommendation of Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734424633.793558564 · Cited by 1
Safety and efficacy of Empagliflozin in Pakistani Muslim Patients with Type 2 Diabetes (SAFE-PAK); A Randomized Clinical TrialPreprint
Aamir, A. H., Raja, U. Y., Qureshi, F. M., Asghar, A., Mahar, S. A., Ahmed, I., Ghaffar, T., Zafar, J., Hasan, M. I., Riaz, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1798584/v1 · Cited by 1
The SGLT2i-mediated regulation of cardiovascular and safety outcomes among patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trialsPreprint
Zhou, Y., Wang, F., Wen, F., Li, C., & Ye, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2453557/v1 · Cited by 1
Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2023)
Muschitz, C., Kautzky‐Willer, A., Winhofer, Y., Rauner, M., Haschka, J., Cejka, D., Wakolbinger, R., & Pietschmann, P. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02118-8 · Cited by 4
Hipertensión y riesgo vascular: editorial a raíz del original «Control de los principales factores de riesgo cardiovascular de la cardiopatía isquémica en prevención secundaria en Aragón: estudio COCINA». Impacto de la diabetes y su control en el riesgo cardiovascular
Gimeno, E. J. (2015) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2015.10.002
Typ-2-Diabetes – Kriterien für die Wahl des Antidiabetikums
Gallwitz, B. (2016) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-106694
Cardiovascular safety of SGLT2 inhibitors
Gumprecht, J. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0007
Empagliflozin: a wonder drug in preventing diabetic nephropathy and cardiovascular effects
Thotakura, N. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20163202
Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes in type 2 diabetes mellitus: A systematic review
Nasr, Z. G., Jalali, F., Ahmed, D., & Wilby, K. J. (2017) · Journal of health specialties · doi:10.4103/2468-6360.198800
Developments in Diabetology in 2016
Kalra, S. (2016) · US Endocrinology · doi:10.17925/use.2016.12.02.78
Glucose lowering therapy of type 2 diabetes – the art of possible
Зуєв, К. О., & Когут, Д. Г. (2016) · Clinical endocrinology and endocrine surgery · doi:10.24026/1818-1384.4(56).2016.87232
Diabetic Ketoacidosis in a Patient with Type 1 Diabetes on Sodium-glucose Co-transporter-2 Inhibitors—a Case Report
Priya, G., & Bhambri, V. (2017) · US Endocrinology · doi:10.17925/use.2017.13.02.72
Modern aspects of the treatment and prevention of diabetes type 2 in patients with metabolic syndrome
Uryasev, O. M., Александровна, М. З., Gorbunova, D. Y., Щербакова, О. Н., & Pyko, A. A. (2017) · Kazan medical journal · doi:10.17750/kmj2017-770
Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors
Iyengar, S. S. (2017) · Hypertension Journal · doi:10.5005/jp-journals-10043-0088
Long-term air pollution exposure and cardiovascular risk factors in older Americans
Honda, T. (2016) · doi:10.17760/d20237645
Harnessing Cardiac Energetics in the Treatment of Heart Failure
Pradhan, A. K. (2016) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0038-1656485
Persistent Diuresis Associated Dapagliflozin Treatment
Gülmez, A., & Gülmez, T. K. (2018) · Turkiye Klinikleri Journal of Case Reports · doi:10.5336/caserep.2018-61023
Cardiovascular Outcomes with Liraglutide: An Update following LEADER
Ghosh, R. (2017) · Open Access Journal of Cardiology · doi:10.23880/oajc-16000101
A patient who does not like insulin
Ubaldi, P. (2018) · AboutOpen · doi:10.19156/abtpn.2018.0057
Oral Glucose-Lowering Agents for the Treatment of Type 2 Diabetes Mellitus
Goh, S. (2019) · The Singapore Family Physician · doi:10.33591/45.1.u1
Type 2 Diabetes Mellitus as a Cardiometabolic Disease
Khoo, C. M. (2019) · The Singapore Family Physician · doi:10.33591/sfp.45.1.u2
INSUFICIENCIA CARDÍACA Y DIABETES
Panzitta, M. C., & Sinay, I. R. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v52i1.85
New Hypoglycaemic Drugs for the Treatment of Diabetes Mellitus and Its Complications: The Future is coming.
Castelao, A. M. (2019) · Open Access Journal of Urology & Nephrology · doi:10.23880/oajun-16000157
Sodium-glucose cotransporter 2 inhibition as a potential treatment for idiopathic oedema
Rambaran, K., Pereira, L. M. P., & Teelucksingh, S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109270
O uso do escore de cálcio, ultrassom de carótidas e teste ergométrico no rastreamento da doença arterial coronária em portadores de diabetes mellitus tipo 2
Rassi, C. H. R. E. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-04092019-092648
Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature
Fabbri, E., & Nizzoli, M. (2019) · Italian Journal of Medicine · doi:10.4081/itjm.2019.1184
Efeitos do inibidor de SGLT2 dapagliflozina na pressão arterial e perfil hemodinâmico em hipertensos resistentes diabéticos
Corrêa, N. B. (2018) · doi:10.47749/t/unicamp.2018.1097427
Tofogliflozin, a SGLT2 inhibitor, improves diabetic ocular complications in Spontaneously Diabetic Torii rats
Toyoda, F., Kobayashi, M., Takagi, R., Tanaka, Y., Shimmura, M., Kinoshita, N., Takano, H., Yamada, H., KAWAKAMI, M., & Kakehashi, A. (2019) · Diabetes Updates · doi:10.15761/du.1000126
Sodium-glucose cotransporter type 2 inhibitors: A new era in the pharmacological treatment of heart failure with reduced ejection fraction?
Torres, Y. C., & Katholi, R. E. (2019) · Journal of Integrative Cardiology · doi:10.15761/jic.1000280
Paradigm shift in the pharmacological treatment of type 2 diabetes mellitus
Lathia, T. B. (2020) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/jmgims.jmgims_40_19
Kardiovaszkuláris prevenció diabetes mellitusban
Vértes, A. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.1
Heart Failure: Novel and Emerging Therapies
Nandiwada, S., Ezekowitz, J. A., & Al-Majed, N. S. (2020) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v15isp1.419
Sodium-glucose co-transporter 2 inhibitors should be the standard of care for treatment of most patients with heart failure and reduced ejection fraction irrespective of presence of diabetes
Mikhail, N. (2020) · Clinical Research and Trials · doi:10.15761/crt.1000288
Recommendations for care of patients with diabetes and kidney impairment
Vachek, J., Zakiyanov, O., & Tesař, V. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.030
Metodologia clinica oggi nel paziente internistico complesso
Nardi, G. E. R., Gnerre, P., Fontanella, A., & Manfellotto, D. (2020) · Italian Journal of Medicine · doi:10.4081/itjm.q.2020.1
Consenso AURORA: risco cardiovascular na pessoa com diabetes mellitus tipo 2
de Família, M., Maricoto, T., Antunes, J. P., de Família, M., Pereira, M. R., de Família, M., Corte-Real, S., de Família, M., Taveira‐Gomes, T., de Família, M., et al. (2020) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v36i3.12744
Should we Take into Account only the Synergy of Action by Combining the New Therapeutics against Diabetes?
Youssouf, B. A. (2019) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2019.11.555823
Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides
Enciso, J. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017666
Oral Relugolix Yields Superior Testosterone Suppression and Decreased Cardiovascular Events Compared With GnRH Agonist
Alsubait (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0011
An Advance Care Planning Video Program in Nursing Homes Did Not Reduce Hospital Transfer and Burdensome Treatment in Long-Stay Residents
Hung, H. (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0012
Attention to Cardiovascular and Renal Complications in Diabetes – how to prevent them?
Lau, T. W. (2020) · The Singapore Family Physician · doi:10.33591/sfp.46.6.u3
Mesa 2: Insuficiencia cardíaca y diabetes mellitus tipo 2
Méndez, J., Martín, C. G., Remón, J., Houssay, S., Forte, E. H., Manfredo, S., Roselli, M., Ré, M., Hernández, D., Margossian, M., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.252
Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Dekkers, C. C. J. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.136049658
Hot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
604 Contemporary Clinical Characteristics and Short-Term Outcomes Following Coronary Artery Bypass Graft Surgery in Patients With Diabetes
Lan, N., Ali, U., Fegan, P. G., Larbalestier, R. I., Hitchen, S. A., Hort, A., & Yeap, B. B. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.611
Treatment of Type 2 Diabetes in Subjects with Obesity: What is the Best Approach?
Ferone, D. (2020) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2020.04.000579
Cognitive Behavioral Therapy Plus Placebo Is Inferior to NSAID Therapy for Arthritis Pain
Hung, H. (2020) · Journal of clinical outcomes management · doi:10.12788/jcom.0029
Satisfying Glycemic Control Achieved by Adding a Sodium-Glucose Co-transporter 2 Inhibitor to Sensor-Augmented Insulin Pump (MiniMed 640G) Therapy in a type 1 Diabetic Woman
Nishimura, A., & Aoki, Y. (2020) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2020.v08i11.008
The New and Evolving Roles of Sodium Glucose Co-Transporter 2 Inhibitors
Irons, B. K. (2020) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2020.04.000585
The treatment of diabetes with new generation drugs
Marosz, S., Borkowska, J., Mikulska, P., Borkowska, K., & Kowieska, J. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.09.083
Consensus on the use of DPP4 Inhibitors and SGLT2 Inhibitors in T2DM with Chronic Kidney Disease-from Indian Context
(2021) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000242
Diabetes and heart failure: time for a new approach
Kaufman, R. (2019) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2019.06.00186
Review of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
From Ptolemy to Copernicus: a new proposal for the care of diabetes
Ponziani, M. C. (2019) · The Journal of AMD · doi:10.36171/jamd19.22.1-2.03
Diabetesa gaixotasun inflamatorio gisa
Alquiza, A., Echeazarra, L., Gallego, M., & Casis, Ó. (2021) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.22710
Diabetes y enfermedad cardiovascular, aspectos actuales de su manejo: la visión del cardiólogo
Ramirez-Ramos, C. F., Betancur-Salazar, K., Castilla-Agudelo, G. A., Saldarriaga, S. C., Aranzazu-Uribe, M., Méndez, D. A. R., Cespedes, E., Montilla, J. F. S., Martínez, C. L., & Saldarriaga, C. (2020) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.7.2.610
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Consensus 2021 for medical management of type 2 diabetes from the diabetes, obesity, and nutrition working group of the Spanish Society of Internal Medicine
Carrasco-Sánchez, F. J., Fern�ndez-Rodr�guez, J. M., Escribano, P. P. C., Miramontes-Gonz�lez, J. P., G�mez-Huelgas, R., Garc�a-de-Lucas, M. D., Ena, J., & Carretero-G�mez, J. (2021) · Spanish Journal of Medicine · doi:10.24875/sjmed.21000010
Cardiovascular ultrasound implementation for a pragmatic approach to the diabetic patient
Greco, E. L. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.3.2
Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction?
Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch14
Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
Afzal, M., Al-Abbasi, F. A., Nadeem, M. S., Alshehri, S., Ghoneim, M. M., Imam, S. S., Almalki, W. H., & Kazmi, I. A. (2021) · Metabolites · doi:10.3390/metabo11110794
¿Más posibilidades de control para el paciente invisible?
Teixidó, C. H. (2021) · doi:10.52102/paciente_invisible/art-5
Paciente frágil con diabetes durante la pandemia
Rivera, A. M. (2021) · doi:10.52102/paciente_invisible/art-1
¿Con qué nos debemos quedar de lo aprendido durante la pandemia?
Lavado, F. J. E. (2021) · doi:10.52102/10.52102/paciente_invisible/art-2
Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2
Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1
Cómo estructurar la atención en el paciente con riesgo cardiovascular elevado en la pospandemia
Gil, F. M. A. (2021) · doi:10.52102/paciente_invisible/art-4
Electrolyte disturbances in heart failure
Beusekamp, J. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.196047233
Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1
Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3
Detección de errores de prescripción, falta de adherencia e inercia terapéutica. Estrategias de mejora
Pradas, N. C. (2021) · doi:10.52102/paciente_invisible/art-3 · Cited by 1
Author response for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1
Efeitos do inibidor de SGLT-2 Dapagliflozina no remodelamento cardiovascular e lesão renal precoce em hipertensos resistentes diabéticos
Pioli, M. R. (2018) · doi:10.47749/t/unicamp.2018.995128
Metabolische Chirurgie: Diabetiker profitieren – unabhängig vom Gewicht
Scheurlen, K. M., Billeter, A. T., & Müller-Stich, B. P. (2018) · Deutsches Ärzteblatt · doi:10.3238/persdia.2018.10.12.02
Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires
Lu, H. Y., Hullin, R., Yerly, P., Meyer, P., Kosinski, C., & Daux, A. (2021) · JMIG · doi:10.53738/revmed.2021.17.740.1034
Influence of Age on the Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients With Type 2 Diabetes Mellitus
Kusunoki, M., Hisano, F., Matsuda, S., Wakazono, N., Tsutsumi, K., & Miyata, T. (2022) · Journal of Endocrinology and Metabolism · doi:10.14740/jem799
SGLT2 Inhibitors and the Associated Risk of Genito Mycotic Infections – A Narrative Review
Sharanya Shre, E. S. (2022) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v5-i5-13
Clinical precision
De Micheli, A. (2019) · The Journal of AMD · doi:10.36171/jamd19.22.1-2.07
Potencial terapêutico das células-tronco mesenquimais na doença renal diabética é mediado pelo efeito antioxidante e modulador no programa de controle de qualidade mitocondrial
Silva, C. (2020) · doi:10.31744/pg2020.106863
Effects of Metformin Monotherapy on Metabolic Parameters in Japanese Patients With Type 2 Diabetes
Katsuyama, H., & Yanai, H. (2019) · Journal of Endocrinology and Metabolism · doi:10.14740/jem549
Optimizing Cardiovascular and Renal Outcomes with Canagliflozin- A Focus on CANVAS and CRENDENCE Trials
Abdelaziz, T. S. (2019) · Online Journal of Cardiology Research & Reports · doi:10.33552/ojcrr.2019.03.000552
Medikamentöse Herzinsuffizienztherapie
Bewarder, Y., Ewen, S., Kindermann, I., & Böhm, M. (2017) · CardioVasc · doi:10.1007/s15027-017-1052-x
Plasma B-Type Natriuretic Peptide Levels May Increase Because of Fat Mass Loss by Metformin or Sodium-Glucose Transporter 2 Inhibitors Treatment
Hamasaki, H., & Yanai, H. (2016) · Journal of Endocrinology and Metabolism · doi:10.14740/jem333w

Authors: Sarafidis, P. A., & Τσάπας, Α.
Affiliations: Aristotle University of Thessaloniki (GR)
ORCID: Pantelis A. Sarafidis
Απόστολος Τσάπας
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-03-17
Volume: 374
Issue: 11
Pages: 1092-1094
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmc1600827
OpenAlex: W2297835124
Cited by: 700
References: 9
Citations by year: 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords: empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
MeSH terms: Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks